Senzime AB (publ) – Trademark Portfolio

Entity Type: 99

Senzime AB (publ) holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 8 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 1 is pending. Notable registered marks include SENZIME, TETRASENS, TETRAGRAPH, and TETRASENSITIVE.

Ulls väg 41

SE-756 51 Uppsala

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Senzime AB (publ)'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (8 filings)

Surgical, medical, dental and veterinary apparatus and instruments

9
Computers & Electronics (2 filings)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does Senzime AB (publ) have?

Senzime AB (publ) has 9 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending, 4 cancelled.

What trademark classes does Senzime AB (publ) file in?

Senzime AB (publ) files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 9 (Computers & Electronics). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Senzime AB (publ)'s most well-known trademarks?

Senzime AB (publ)'s registered trademark portfolio includes well-known marks such as SENZIME, TETRASENS, TETRAGRAPH, and TETRASENSITIVE. These are among 4 currently registered trademarks in the portfolio.

What is Senzime AB (publ)'s trademark registration success rate?

Senzime AB (publ) has a 50% trademark registration rate, with 4 out of 8 resolved applications resulting in successful registration. Currently, 1 application is pending review.